Why the study?
Adenosine is commonly used prehospital for PSVT, but initial dosing varies and the optimal first dose is unknown.
Does an initial prehospital adenosine dose of 12 mg improve patient response and reduce hospital admissions compared to 6 mg in patients with presumed PSVT?
Does an initial prehospital adenosine dose of 12 mg improve patient response and reduce hospital admissions compared to 6 mg in patients with presumed PSVT?
An initial prehospital adenosine dose of 12 mg for presumed PSVT is associated with greater patient improvement, less need for re-dosing, and fewer hospital admissions compared to 6 mg, without an increase in complications.
Initial 12 mg adenosine was associated with improved prehospital conversion and fewer admissions versus 6 mg in PSVT; leaves open need for randomized confirmation before practice change.
Objectives Adenosine is a common prehospital treatment for paroxysmal supraventricular tachycardia (PSVT); however initial dosing varies and the optimal first dose is unknown. To evaluate the association of the two common initial adenosine dosing regimens (6 mg and 12 mg) with prehospital patient improvement, hospital admission, complications, and death.Methods This retrospective observational study included all 9-1-1 responses with prehospital adenosine administration between 1/1/2022 and 12/31/2022 from the ESO Data Collaborative. Outcomes included EMS clinician documented patient response (improved v. unchanged/worse) to the initial dose, emergency department (ED) dispositions, compressions/cardioversion/pacing after adenosine administration, and death. Descriptive statistics and adjusted odds ratios (OR) were used to compare outcomes for patients who received an initial adenosine dose of 6 mg versus 12 mg.Results We analyzed 11,245 patients that received adenosine from 1,350 EMS agencies. Most received an initial dose of 6 mg (70%, n = 7,825), while 30% (n = 3,314) received an initial dose of 12 mg. Initial pulse rate and systolic blood pressure were similar between groups. Nearly half in the 6 mg group (48%, n = 3,746) received additional doses, compared to 25% (n = 815) in the 12 mg group. An initial dose of 12 mg was associated with 65% increased odds of prehospital improvement (OR: 1.65, 95%CI: 1.49–1.82). Complications including cardioversion (5%, n = 481), pacing (<1%, n = 2), and cardiopulmonary resuscitation (CPR) (<1%, n = 20) were rare. There was no difference in the need for cardioversion, pacing, or CPR between groups (p > 0.05). Amongst EMS transported patients, 25% (n = 2,732) had available ED dispositions. An initial dose of 12 mg was associated with a 28% reduction in odds of admission (OR: 0.72, 95%CI: 0.59–0.87). In total, 2% (n = 48) who received prehospital adenosine and had available outcome data died. Of those, 70% (n = 32) were in the 6 mg group and 30% (n = 14) were in the 12 mg group.Conclusions An initial prehospital adenosine dose of 12 mg was associated with less re-dosing, greater rates of patient improvement, and lower rates of hospital admission compared to an initial dose of 6 mg. Complications requiring interventions and death were rare and similar across dosing regimens.
No takes yet. Share an insight, caveat, or question.
Fernandez et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: